semaglutide cough Oral Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients GLP1 weight loss drugs linked

Korsatko S, Jensen L, Brunner M, Sach-Friedl S, Tarp MD, Holst AG, Heller SR, Pieber TR

After 52 weeks, participants who took 36 milligrams of orforglipron saw a key blood sugar marker reduce by nearly 2 percent, while those who received 14 milligrams of oral semaglutide saw levels drop by nearly 1.5 percent

In the quest to combat this epidemic, researchers have been exploring new drugs, including retatrutide, a novel triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors

The peptides effects on tendon and ligament health prove particularly relevant for sports involving rapid direction changes, jumps, and high-impact landings

J Assoc Physicians India 2018;66:3740